229 related articles for article (PubMed ID: 25220628)
1. Targeting HER2 in ovarian and uterine cancers: challenges and future directions.
Teplinsky E; Muggia F
Gynecol Oncol; 2014 Nov; 135(2):364-70. PubMed ID: 25220628
[TBL] [Abstract][Full Text] [Related]
2. Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance.
Carvajal-Hausdorf DE; Schalper KA; Bai Y; Black J; Santin AD; Rimm DL
Gynecol Oncol; 2017 Apr; 145(1):154-158. PubMed ID: 28196634
[TBL] [Abstract][Full Text] [Related]
3. Eradication of growth of HER2-positive ovarian cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate in mouse xenograft model.
Yu L; Wang Y; Yao Y; Li W; Lai Q; Li J; Zhou Y; Kang T; Xie Y; Wu Y; Chen X; Yi C; Gou L; Yang J
Int J Gynecol Cancer; 2014 Sep; 24(7):1158-64. PubMed ID: 24987913
[TBL] [Abstract][Full Text] [Related]
4. HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy.
McAlpine JN; Wiegand KC; Vang R; Ronnett BM; Adamiak A; Köbel M; Kalloger SE; Swenerton KD; Huntsman DG; Gilks CB; Miller DM
BMC Cancer; 2009 Dec; 9():433. PubMed ID: 20003286
[TBL] [Abstract][Full Text] [Related]
5. HER2 aberrations in cancer: implications for therapy.
Yan M; Parker BA; Schwab R; Kurzrock R
Cancer Treat Rev; 2014 Jul; 40(6):770-80. PubMed ID: 24656976
[TBL] [Abstract][Full Text] [Related]
6. T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2.
Nicoletti R; Lopez S; Bellone S; Cocco E; Schwab CL; Black JD; Centritto F; Zhu L; Bonazzoli E; Buza N; Hui P; Mezzanzanica D; Canevari S; Schwartz PE; Rutherford TJ; Santin AD
Clin Exp Metastasis; 2015 Jan; 32(1):29-38. PubMed ID: 25398397
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.
Krop IE; LoRusso P; Miller KD; Modi S; Yardley D; Rodriguez G; Guardino E; Lu M; Zheng M; Girish S; Amler L; Winer EP; Rugo HS
J Clin Oncol; 2012 Sep; 30(26):3234-41. PubMed ID: 22649126
[TBL] [Abstract][Full Text] [Related]
8. [T-DM1 and pertuzumab: emerging anti-HER2 therapeutics].
Noguchi E; Shimizu C
Gan To Kagaku Ryoho; 2013 Jan; 40(1):10-4. PubMed ID: 23306913
[TBL] [Abstract][Full Text] [Related]
9. HER2-directed therapy: current treatment options for HER2-positive breast cancer.
Ahmed S; Sami A; Xiang J
Breast Cancer; 2015 Mar; 22(2):101-16. PubMed ID: 25634227
[TBL] [Abstract][Full Text] [Related]
10. Use of pertuzumab for the treatment of HER2-positive metastatic breast cancer.
De Mattos-Arruda L; Cortes J
Adv Ther; 2013 Jul; 30(7):645-58. PubMed ID: 23881722
[TBL] [Abstract][Full Text] [Related]
11. Emerging strategies for the dual inhibition of HER2-positive breast cancer.
Konecny GE
Curr Opin Obstet Gynecol; 2013 Feb; 25(1):55-65. PubMed ID: 23241641
[TBL] [Abstract][Full Text] [Related]
12. Targeting HER2 for the treatment of breast cancer.
Rimawi MF; Schiff R; Osborne CK
Annu Rev Med; 2015; 66():111-28. PubMed ID: 25587647
[TBL] [Abstract][Full Text] [Related]
13. The Therapeutic Challenge of Targeting HER2 in Endometrial Cancer.
Diver EJ; Foster R; Rueda BR; Growdon WB
Oncologist; 2015 Sep; 20(9):1058-68. PubMed ID: 26099744
[TBL] [Abstract][Full Text] [Related]
14. [Systemic treatments of inflammatory breast cancer: an overview].
Monneur A; Bertucci F; Viens P; Gonçalves A
Bull Cancer; 2014 Dec; 101(12):1080-8. PubMed ID: 25475708
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group.
Bookman MA; Darcy KM; Clarke-Pearson D; Boothby RA; Horowitz IR
J Clin Oncol; 2003 Jan; 21(2):283-90. PubMed ID: 12525520
[TBL] [Abstract][Full Text] [Related]
16. The distinctive nature of HER2-positive gastric cancers.
Marano L; Roviello F
Eur J Surg Oncol; 2015 Mar; 41(3):271-3. PubMed ID: 25605551
[No Abstract] [Full Text] [Related]
17. HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies.
English DP; Roque DM; Santin AD
Mol Diagn Ther; 2013 Apr; 17(2):85-99. PubMed ID: 23529353
[TBL] [Abstract][Full Text] [Related]
18. Targeting human epidermal growth factor receptor 2 (HER2) in gynecologic malignancies.
Erickson BK; Zeybek B; Santin AD; Fader AN
Curr Opin Obstet Gynecol; 2020 Feb; 32(1):57-64. PubMed ID: 31833974
[TBL] [Abstract][Full Text] [Related]
19. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.
Scaltriti M; Rojo F; Ocaña A; Anido J; Guzman M; Cortes J; Di Cosimo S; Matias-Guiu X; Ramon y Cajal S; Arribas J; Baselga J
J Natl Cancer Inst; 2007 Apr; 99(8):628-38. PubMed ID: 17440164
[TBL] [Abstract][Full Text] [Related]
20. Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer.
Baron JM; Boster BL; Barnett CM
J Oncol Pharm Pract; 2015 Apr; 21(2):132-42. PubMed ID: 24682654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
